Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Environmental Pathology, Toxicology and Oncology
CiteScore™: 1.61 IF: 1.15 5-Year IF: 1.4 SNIP: 0.613 SJR: 0.519

ISSN Print: 0731-8898
ISSN Online: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.v26.i2.60
pages 117-126

Fluorescence Monitoring of a Topically Applied Liposomal Temoporfin Formulation and Photodynamic Therapy of Nonpigmented Skin Malignancies

Niels Bendsoe
Department of Dermatology, Lund University Hospital, Lund University Medical Laser Centre, SE-221 00 Lund, Sweden; Department of Dermatology, Lund University Hospital, SE-221 85 Lund, Sweden
Linda Persson
Department of Physics, Lund University, Lund, Sweden
Ann Johansson
Department of Physics, Lund University, Lund, Sweden
Johan Axelsson
Department of Physics, Lund University, Lund, Sweden
Jenny Svensson
Department of Physics, Lund University, Lund, Sweden
Susanna Grafe
Research & Development, Biolitec AG, Jena, Germany
Tilmann Trebst
Research & Development, Biolitec AG, Jena, Germany
Stefan Andersson-Engels
Lund University Medical Laser Centre; Department of Physics, Lund Institute of Technology, SE-221 00 Lund, Sweden
Sune Svanberg
Lund University Medical Laser Centre; Department of Physics, Lund Institute of Technology, SE-221 00 Lund, Sweden
Katarina Svanberg
Lund University Medical Laser Centre; Department of Oncology, Lund University Hospital, SE-221 85 Lund, Sweden

ABSTRACT

Meso-tetra(hydroxyphenyl)chlorin (mTHPC) (INN: Temoporfin) is a potent photodynamically active substance in clinical use today. Usually, the substance is given systemically and a known drawback with this administration route is a prolonged skin light sensitization. For the first time to our knowledge, a liposomal Temoporfin gel formulation for topical application was studied in connection with photodynamic therapy (PDT) of nonpigmented skin malignancies in humans. Intervals of 4 hr between drug administration and light irradiation were used. Sensitizer distribution within tumor and surrounding normal skin was investigated by means of point monitoring and imaging fluorescence spectroscopy before, during, and after PDT, showing high tumor selectivity. Furthermore, the bleaching of Temoporfin was studied during the PDT procedure by monitoring the fluorescence following excitation by using a therapeutic light. A 30−35% light-induced photometabolization was shown. No pain occurred during or after treatment. It was also observed that the treated area did not show any swollen tissue or reddening, as is often seen in PDT using topical δ-aminolevulinic acid. On controlling the patients one week after treatment, healing progress was observed in several patients and no complications were registered.